Three publications confirm the effectiveness of the FR104, Effimune’s leading molecule

1 December 2015

effimune-200x200Effimune announced , the publication in leading scientific journals of three different studies confirming the efficacy of FR104 in new preclinical models, and suggesting that it could be a potent new treatment for rheumatoid arthritis and psoriasis.
The three studies confirm CD28 as an interesting target and FR104 as a potential tool in immune regulation. They demonstrate the effectiveness of the drug candidate in different preclinical models of autoimmune inflammatory diseases:

  • Two models of skin inflammation similar to human psoriasis
  • A model of joint inflammation associated with rheumatoid arthritis


Read the full press release